SENSEX NIFTY
You are here : Moneycontrol > Mutual Funds > Sector - Pharma & Healthcare > SBI Mutual Fund > SBI Pharma Fund - Direct Plan (D)

SBI Pharma Fund - Direct Plan (D) SET SMS ALERT

88.354
0.29 (0.33%)
NAV as on Oct-17-2014
NAV as on Oct-17-2014
ranking by CRISIL

Not Ranked

This scheme is not ranked by CRISIL (for quarter ended Mar 2014) since it does not fulfill certain eligibility criteria of CRISIL

View Top ranked funds in other categories

Benchmark Index:
 
View Historic Graph From     To     

Returns (NAV as on Oct-17-2014)

Period Returns (%) Rank #
1 mth -2.8 3
3 mth 12.6 5
6 mth 31.8 1
1 year 47.2 3
2 year - -
3 year - -
5 year - -

# Moneycontrol Rank within 6 Sector - Pharma & Healthcare Schemes.

Absolute Returns (in %)

Year Qtr 1 Qtr 2 Qtr 3 Qtr 4 Annual
2014 4.1 15.1 23.9 - -
2013 -4.0 9.2 6.6 8.6 25.0

View where it stands within its peers

* Returns over 1 year are Annualised

Performance

Fund returns v/s Category average (Sector - Pharma & Healthcare)

* Returns over 1 year are Annualised
  1 mth (%) 3 mth (%) 6 mth (%) 1 yr (%) 2 yr (%) 3 yr (%) 5yr (%)
Fund Returns -2.8 12.6 31.8 47.2 -- -- --
Category avg -2.7 15.2 30.1 48.2 16.9 15.0 12.4
Difference of Fund returns and Category returns -0.1 -2.6 1.7 -1.0 -- -- --
Best of category -1.8 19.3 31.8 56.9 36.5 35.0 25.6
Worst of category -3.3 12.4 27.2 41.0 32.0 26.2 23.4
Benchmark returns # -1.7 13.7 28.2 39.6 33.3 31.7 24.7
Difference of Fund returns and Benchmark returns -1.1 -1.1 3.6 7.6 -- -- --
# Benchmark Index: S&P BSE HEALTHCARE

Investment Info

Investment Objective

To provide the investors maximum growth opportunity through equity investments in stocks of growth oriented sectors of the economy. There are five sub-funds dedicated to specific investment themes viz. Information Technology,Pharmaceuticals, FMCG, Contrarian (investment in stocks currently out of favour) and Emerging Businesses.

Scheme details

Fund Type Open-Ended
Investment Plan Dividend
Launch date Jan 01, 2013
Benchmark S&P BSE HEALTHCARE
Asset Size (Rs cr) 21.33 (Jun-30-2014)
Minimum Investment Rs.50000
Last Dividend N.A. View Dividend History
Bonus N.A.
Fund Manager Tanmaya Desai
View performance of schemes managed by the Fund Manager
Notes N.A

Load Details

Entry Load N.A
Exit Load 0.00%
Load Comments Exit load charge will be nil w.e.f. Oct 10, 2013.

Contact Details

Regd. Office 191 Maker Towers E, Cuffe Parade, Mumbai, 400005
Tel. No. 91 22 22180221/ 27
Fax No. 91 22 22189663
Email partnerforlife@sbimf.com
Website http://www.sbimf.com

Peer Comparison

Sector - Pharma & Healthcare Crisil Rank Assets (Rs.cr)
3mth (%) 6mth (%) 1yr (%) 3yr (%) 5yr (%)
Reliance Pharma Fund (G) Not Ranked
773.24 19.1 31.1 55.7 28.8 25.6
SBI Pharma Fund (G) Not Ranked
194.91 12.4 31.2 46.0 35.0 25.4
UTI Pharma & Health (G) Not Ranked
149.44 13.6 27.2 41.0 26.2 23.4
Reliance Pharma Fund - Direct (G) Not Ranked
36.13 19.3 31.6 56.9 -- --
SBI Pharma Fund - Direct (G) Not Ranked
21.33 12.6 31.8 47.2 -- --
* Returns over 1 year are Annualised More »

Portfolio

Top Holdings (Sep 30, 14)

Equity Sector Value
(Rs cr)
Asset %
Sun Pharma Pharmaceuticals 6.92 24.25
Lupin Pharmaceuticals 3.44 12.06
Dr Reddys Labs Pharmaceuticals 3.04 10.65
Aurobindo Pharm Pharmaceuticals 2.17 7.60
Divis Labs Pharmaceuticals 2.10 7.35
Ranbaxy Labs Pharmaceuticals 1.84 6.43
Cadila Health Pharmaceuticals 1.54 5.41
Strides Arcolab Pharmaceuticals 1.16 4.05
Torrent Pharma Pharmaceuticals 1.09 3.82
Natco Pharma Pharmaceuticals 0.92 3.22

Full Portfolio

Sector Allocation (Sep 30, 14)

Sector %

1-Year

HighLow

Pharmaceuticals 97.79 98.66 96.68

View All Sectors

Asset Allocation (%)(Sep 30, 14)

Equity 97.79
Others 0.12
Debt 0.00
Mutual Funds N.A
Money Market 2.29
Cash / Call -0.20

View All

Concentration

Holdings (%)
Top 5 61.91
Top 10 84.84
Sector (%)
Top 3 97.79

News & Videos

News

Messages & Community

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.